II. which is the better choice for second- line treatment?; BEV or anti-EGFR after BEV treatment in patients with unresectable wild type K-ras colon cancer
Osera, S.; Shitara, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(11): 1459
2013
ISSN/ISBN: 0385-0684 PMID: 24319792 Document Number: 669742
Document emailed within 1 workday
Related Documents
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188Urata, Y.; Satouchi, M. 2015: I. what is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer? Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(8): 931-934
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Kargi, A.; Yalcin, A.D.; Erin, N.; Savas, B.; H. Hüseyin Polat; Gorczynski, R.M. 2012: IL8 and Serum Soluble Trail Levels Following Anti-VEGF Monoclonal Antibody Treatment in Patients With Metastatic Colon Cancer Clinical Laboratory 58(5-6): 501-505
Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
Maruo, H.; Suzuki, K.; Ishikawa, S.; Murakami, T.; Higashi, Y.; Shoji, T.; Yamazaki, M.; Taniguchi, M.; Nishiyama, R. 2014: Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(13): 2583-2586
Skoularigis, J.; Strugo, V.; Radevski, I.; Hlatswayo, Z.; Sareli, P. 1997: Once-daily fixed dose combinations of verapamil and trandolapril in black patients with mild to moderate hypertension: a new choice for first line treatment International Journal of Clinical Pharmacology and Therapeutics 35(2): 51-55
Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
Soeda, H.; Shimodaira, H.; Ishioka, C. 2011: Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1079-1083
Yang, B.; Zheng, D.; Zeng, Υa.; Qin, A.; Gao, J.; Yu, G. 2018: Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(4): 1077-1081
Shi, Y. 2015: The Guideline for Diagnosis and Treatment of Chinese Patients with sensitizing EGFR Mutation or ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2015 Version) Zhonghua Zhong Liu Za Zhi 37(10): 796-799
Ohkusa, T.; Watanabe, M. 2001: A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment Nihon Rinsho. Japanese Journal of Clinical Medicine 59(2): 323-327
Gavrilov, V.; Steiner, M.; Shany, S. 2005: The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth Anticancer Research 25(5): 3425-3429
1989: Diagnosis and first-line treatment of patients with lung cancer in Italian general hospitals. G.I.V.I.O. (Interdisciplinary Group for Cancer Evaluation) Tumori 75(2): 163-167
Eriukhin, I.A.; Akinchev, S.L.; Maksimov, G.K.; Sinitsin, A.N. 1985: Prognosis of the results of the surgical treatment of patients with cancer of the colon Voprosy Onkologii 31(4): 53-59
Wang, Y.; Szekely, L.; Okan, I.; Klein, G.; Wiman, K.G. 1993: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line Oncogene 8(12): 3427-3431
Cao, H.; Wang, M. 2014: Diagnosis and treatment of wild-type gastrointestinal stromal tumors Zhonghua Wei Chang Wai Ke Za Zhi 17(4): 312-316
Maiello, E.; Giotta, F.; Gebbia, V.; Testa, A.; Galetta, D.; Riccardi, F.; Gebbia, N.; Colucci, G. 1996: Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients Anticancer Research 16(5b): 3177-3179
Fitzpatrick, J.M. 1996: Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against European Urology 29(Suppl): 37-39
Zhang, J.Q.; Xu, F.; Xu, X.L.; Zhou, H.C. 2017: Erlotinib in the treatment of small cell lung cancer with EGFR mutation: a case report Zhonghua Zhong Liu Za Zhi 39(9): 717-719